RXRX icon

Recursion Pharmaceuticals

5.28 USD
-0.44
7.69%
At close Jul 11, 4:00 PM EDT
Pre-market
5.25
-0.03
0.57%
1 day
-7.69%
5 days
1.93%
1 month
-2.22%
3 months
-8.33%
6 months
-21.66%
Year to date
-26.77%
1 year
-31.25%
5 years
-83.13%
10 years
-83.13%
 

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Employees: 800

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

106% more repeat investments, than reductions

Existing positions increased: 138 | Existing positions reduced: 67

61% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 41

30% more call options, than puts

Call options by funds: $28.3M | Put options by funds: $21.7M

7% more funds holding

Funds holding: 312 [Q4 2024] → 333 (+21) [Q1 2025]

2.41% less ownership

Funds ownership: 79.42% [Q4 2024] → 77.01% (-2.41%) [Q1 2025]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2024] → 9 (-1) [Q1 2025]

22% less capital invested

Capital invested by funds: $2.06B [Q4 2024] → $1.61B (-$451M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
5%
downside
Avg. target
$6.50
23%
upside
High target
$8
52%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Needham
Gil Blum
52%upside
$8
Buy
Reiterated
8 Jul 2025
Morgan Stanley
Vikram Purohit
5%downside
$5
Equal-Weight
Assumed
3 Jul 2025

Financial journalist opinion

Based on 12 articles about RXRX published over the past 30 days

Positive
Zacks Investment Research
3 days ago
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Positive
Zacks Investment Research
4 days ago
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Positive
The Motley Fool
5 days ago
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
It's not exactly a secret that big technology stocks like Microsoft, Nvidia, and Alphabet have led the market for several years now. And rightfully so.
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
Positive
The Motley Fool
5 days ago
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Shares in biotech company Recursion Pharmaceuticals (RXRX 10.65%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Neutral
Forbes
6 days ago
What's Happening With RXRX Stock?
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and machine learning.
What's Happening With RXRX Stock?
Negative
The Motley Fool
6 days ago
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market
There's little doubt that artificial intelligence is here to stay. It's just too game-changing to put back in the box now.
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market
Positive
Zacks Investment Research
6 days ago
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Positive
Zacks Investment Research
1 week ago
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
Positive
Zacks Investment Research
1 week ago
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Neutral
Zacks Investment Research
2 weeks ago
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Charts implemented using Lightweight Charts™